Literature DB >> 34400316

Unraveling the roles of miRNAs in regulating epithelial-to-mesenchymal transition (EMT) in osteosarcoma.

Zhi Xiong Chong1, Swee Keong Yeap2, Wan Yong Ho3.   

Abstract

Osteosarcoma is one of the most prevalent primary bone tumors with a high metastatic and recurrence rate with poor prognosis. MiRNAs are short and non-coding RNAs that could regulate various cellular activities and one of them is the epithelial-to-mesenchymal transition (EMT). Osteosarcoma cells that have undergone EMT would lose their cellular polarity and acquire invasive and metastatic characteristics. Our literature search showed that many pre-clinical and clinical studies have reported the roles of miRNAs in modulating the EMT process in osteosarcoma and compared to other cancers like breast cancer, there is a lack of review article which effectively summarizes the various roles of EMT-regulating miRNAs in osteosarcoma. This review, therefore, was aimed to discuss and summarize the EMT-promoting and EMT-suppressing roles of different miRNAs in osteosarcoma. The review would begin with the discussion on the concepts and principles of EMT, followed by the exploration of the diverse roles of EMT-regulating miRNAs in osteosarcoma. Subsequently, the potential use of miRNAs as prognostic biomarkers in osteosarcoma to predict the likelihood of metastases and as therapeutic agents would be discussed.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; EMT-regulating miRNAs; Epithelial-to-mesenchymal transition (EMT); MiRNAs; Osteosarcoma; Therapeutic agent

Mesh:

Substances:

Year:  2021        PMID: 34400316     DOI: 10.1016/j.phrs.2021.105818

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  8 in total

1.  [MiR-671-5p negatively regulates SMAD3 to inhibit migration and invasion of osteosarcoma cells].

Authors:  Y Hu; D Liang; X Chen; L Chen; J Bai; H Li; C Yin; W Zhong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-10-20

2.  [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].

Authors:  L Shang; W Jiang; J Zhang; W Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

3.  Integrated analyses of an RNA binding protein-based signature related to tumor immune microenvironment and candidate drugs in osteosarcoma.

Authors:  Abdulraheem Gul Mohammad; Dapeng Li; Rong He; Xuan Lei; Lianghao Mao; Bing Zhang; Xinyu Zhong; Zhengyu Yin; Wenbing Cao; Wenchao Zhang; Ruoxuan Hei; Qiping Zheng; Yiming Zhang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

4.  Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating β-catenin via HIF-1α/BNIP3/LC3B-mediated mitophagy pathway.

Authors:  Guanping He; Jing-Jun Nie; Xiao Liu; Zihao Ding; Peng Luo; Yu Liu; Bo-Wen Zhang; Renxian Wang; Xiaoguang Liu; Yong Hai; Da-Fu Chen
Journal:  Bioact Mater       Date:  2022-05-13

5.  A Novel Small Molecular Inhibitor of DNMT1 Enhances the Antitumor Effect of Radiofrequency Ablation in Lung Squamous Cell Carcinoma Cells.

Authors:  Yuan-Yuan Liu; Cheng-Zhi Ding; Jia-Ling Chen; Zheng-Shuai Wang; Bin Yang; Xiao-Ming Wu
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

6.  No Effect on Tumorigenesis in MG63 Cells Induced by Co-Cultured Mesenchymal Stem Cells.

Authors:  Xin Xing; Yue-Hua Hu; Yan Wang; Yi Shao; Min Zou
Journal:  J Oncol       Date:  2022-07-06       Impact factor: 4.501

Review 7.  Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma.

Authors:  Xiaozhuo Gao; Bo Gao; Shenglong Li
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 8.  Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers.

Authors:  Guillaume Anthony Odri; Joëlle Tchicaya-Bouanga; Diane Ji Yun Yoon; Dominique Modrowski
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.